Viewing Study NCT00496028



Ignite Creation Date: 2024-05-05 @ 5:36 PM
Last Modification Date: 2024-10-26 @ 9:34 AM
Study NCT ID: NCT00496028
Status: COMPLETED
Last Update Posted: 2010-09-22
First Post: 2007-07-03

Brief Title: Phase I Study in Patients With Solid Tumours
Sponsor: AstraZeneca
Organization: AstraZeneca

Study Overview

Official Title: A Phase I Open-label Study to Assess the Safety and Tolerability of AZD0530 in Combination With Carboplatin andor Paclitaxel Chemotherapy in Patients With Solid Tumours
Status: COMPLETED
Status Verified Date: 2010-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study will comprise 2 parts a dose escalation phase and a dose expansion phase The 2 phases are part of a single study and described by this single protocol Patients entered into the dose escalation phase will not be entered into the expansion phase All subjects must be suitable for treatment with either carboplatin andor paclitaxel
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
AZD0530 study 23 None None None